Contact

UK Office

Only Medics
33 Blagrave Street
Reading, Berkshire
RG1 1PW, UK

Tel -
+44(0)1189 522799

Email -
info@onlymedics.com

EU Office

Only Medics
11 - 12 Bouverie Street
London
EC4Y 8DP, UK

Tel -
+44(0)2078 221719

Share &
Connect


Keep connected & join the Only Medics Network here.

Only Medics LinkedIn Only Medics Facebook Only Medics Twitter
Clinical Professionals Pinterest Clinical Professionals YouTube Only Medics Google+
Pharmaceutical Jobs Integrated Regulatory Outsourcing Medical Communication Jobs
  • AstraZeneca drug found to lower oral steroid use for asthma

    May 23, 2017 Patients with severe and uncontrolled asthma found that taking AstraZeneca's experimental drug benralizumab in a late-stage study either significantly reduced the need or stopped altogether their intake of oral corticosteroids (OCS), the drug was also shown to dramatically cut related hospitalisatio...

  • Biogen pays $120 million to Remedy Pharmaceuticals for stroke treatment Cirara

    May 17, 2017 The US biotech announces that it has licensed a late-stage stroke drug that could be the first treatment advancement in the therapy area since the 1990s. Biogen will pay Remedy Pharmaceuticals $120 million for Cirara, which is currently heading towards Phase III trials in ischaemic stroke. If ...

  • Bid for European Medicines Agency made by Ireland

    May 10, 2017 As European Union leaders prepare for Brexit negotiations with the UK, Ireland has stepped up its bid to make Dublin the new home of the EU’s medicines agency. The EMA looks relatively certain to leave its current residence in east London because of Brexit, and many EU cities are eager to...

  • Report warns that UK GPs are lacking in psoriasis training

    May 03, 2017 Report by The Patient Association in association with Danish pharmaceutical company, LEO Pharma, has highlighted a significant gap between training and support available for primary care and needs of those living with psoriasis in the UK and Ireland.Approximately two million people are currently liv...

  • Over 30% of cancer cases in England are diagnosed as an emergency

    Apr 26, 2017 A Cancer Research UK funded study published in the British Journal of General Practice has found more than one third (34%) of patients are diagnosed with cancer as an emergency in England had not visited their GP beforehand, which is hindering their chances of achieving the best treatment outcomes.D...

  • British Medical Association implores politicians to focus on NHS in upcoming election

    Apr 19, 2017 The BMA is urging politicians to take on the NHS crisis in their pre-general election manifestos.Prime Minister Theresa May announced earlier this week that there will be a snap general election in the UK on June 8th, to “secure the strong and stable leadership the country needs to see us thro...

  • Scotland first UK nation to routinely offer HIV PrEP along with Psoriasis, MS and CLL treatments

    Apr 11, 2017 Scotland is set to become the first UK nation to routinely offer HIV pre-exposure prophylaxis to eligible patients after the Scottish Medicines Consortium backed the use of Gilead’s Truvada along with four other new therapies to be funded by the NHS.In clinical trials Truvada (emtricitabine/te...

  • GW Pharmaceuticals gains orphan status for rare epilepsy cannabinoid Epidiolex

    Apr 05, 2017 UK-based GW Pharmaceuticals’ cannabinoid Epidiolex has been awarded Orphan status by European regulators as treatment for Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy.The approval follows data from two late-stage trials that showed when Epidiolex was added ...

  • NHS England plans to remove “Low-value” prescriptions such as sun cream and gluten free food

    Mar 29, 2017 NHS England has announced a review that could lead prescriptions deemed to be low value such as sun cream and gluten-free foods could soon be unavailable on the NHS in England.   The plan follows extensive work by NHS Clinical Commissioners, who identified significant areas where savings...

  • New Pfizer antibiotic, Zavicefta launched in UK

    Mar 16, 2017 Zavicefta has now been launched in the UK to treat serious aerobic Gram-negative infections caused by antibiotic resistant bacteria.The Pfizer drug is a fixed combination of avibactam, a new beta-lactamase inhibitor, and ceftazidime, an antibiotic belonging to the class of third generation cephalosp...

  • Universities in Scotland to collaborate on stem cell therapy development

    Mar 09, 2017 Researchers at the Universities of Dundee and Edinburgh in Scotland will be working with the pharmaceutical industry to improve understanding of the biological processes that could form the basis of new therapies to support tissue regeneration or repair.The National Phenotypic Screening Centre (NPSC...

  • New specialised treatments cleared for NHS funding

    Mar 02, 2017 NHS England announces three new specialised treatments are to be made available on the NHS for patients in England after initial rejection for funding back in December.Funding has been now been approved for second allogeneic haematopoietic stem cell transplants (also known as bone marrow transplants...

  • NHS files £886 million year to date deficit

    Feb 23, 2017 Figures published by NHS Improvement shows that NHS provider sector has generated a year-to-date deficit of £886 million, with the sector forecasting a year-end deficit of £873m.According to the regulator, NHS providers are "experiencing one of the most challenging winters on record" due...

  • NICE states digital heart scan could save the NHS millions

    Feb 16, 2017 Digital heart scanning software created by HeartFlow that can assess the cause of chest pain, has been recommended for use on the NHS, with the potential of saving the health service millions.  England and Wales’ cost effectiveness watchdog NICE says the HeartFlowFFRCT could replace...

  • Designer compound may aid damage that leads to some dementias

    Feb 10, 2017 In a study of mice and monkeys, NIH funded researchers showed that they could prevent and reverse some of the brain injury caused by the toxic form of a protein called tau. The results, published in Science Translational Medicine, suggest that the study of compounds, called tau antisense oligonucleo...

  • BHF estimates half a million people in the UK could be of risk of sudden death

    Feb 02, 2017 The British Heart Foundation has estimated that approximately 620,000 people in the UK are potentially carrying a faulty gene that puts them at high risk sudden death, but the foundation warns majority of carriers are unaware.The charity also noted that an accurate figure could be much higher due to...

  • MHRA accept Roche’s bladder cancer immunotherapy drug for Early Access to Medicines Scheme

    Jan 26, 2017 Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer.The decision means that patients suffe...

  • AstraZeneca expands their first line cancer immunotherapy programme

    Jan 18, 2017 AstraZeneca has expanded a late-stage trial that assess a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy.The Phase III MYSTIC trial was originally designed to ass...

  • Allergan increases pipeline with Parkinson’s deal

    Jan 10, 2017 Allergan has stepped into the field of Parkinson's disease with an option to acquire US-based neurodegenerative research group Lysosomal Therapeutics (LTI). LTI-291, LTI's lead programme, is designed to stimulate the activity of glucocerebrosidase (GCase) in the brain, which is reduced in many ...

  • Lasting immune impression could enhance blood cancer treatments

    Jan 05, 2017 The human body has a built-in army to help combat against disease, the immune system. In addition to fighting off bacteria and viruses it can also help combat tumours. That’s why researchers are attempting to rally these cells to treat cancer, leading to some significant advances being made ov...

  • Merry Christmas and a Happy New Year from Only Medics

    Dec 23, 2016 Over the past couple of weeks, employees from Only Medics, part of the Clinical Professionals Group, have been busy filling boxes with presents for the Rotary Club Shoebox scheme. The Rotary Club is a UK based charity that was founded in 1905, with the goal of creating a global network of volunte...

  • Cancer Research UK reports immunotherapy drug that can extend life of cancer patients

    Dec 15, 2016 A drug that ‘reinvigorates the immune system’ can extend the lives of lung cancer patients with reduced side effects, according to preliminary results from a late stage clinical trial. “This is another great example of how research into the immune system can deliver powerful new t...

  • NHS England unveils investment in cancer services

    Dec 09, 2016 Chief executive of NHS England, Simon Stevens, has unveiled the first fraction of hospitals that will benefit from a major national investment in NHS radiotherapy machines.   Fifteen hospitals in areas where there is greatest need have now been selected to receive new LINAC linear (accel...

  • Oral Cancer Rates within the UK has Risen by 68% over the past 20 Years.

    Dec 01, 2016 To raise awareness during Mouth Cancer Action Month, Cancer Research UK (CRUK) has released figures of an analysis that reveals the rate of oral cancer has risen by 68% in men and women of all ages over the last 20 years. Annual cases in men under 50 have climbed from 340 to around 640, a growth of...

  • Number of Prescribed Antibiotics Has Fallen for the First Time in England

    Nov 23, 2016 Doctors in England have prescribed 2.2 million less antibiotics between 2014 to 2015. Data from Public Health England has shown a significant reduction of 40.7 million to 38.5. A report by the 'English Surveillance Programme for Antimicrobial Utilisation and Resistance' (ESPAUR) stated the 4.3 ...

  • Lung function test used to diagnose COPD can aid patients whilst reducing healthcare costs

    Nov 16, 2016 According to a recent study by the Canadian Medical Association Journal (CMAJ), patients with chronic obstructive pulmonary disease (COPD) would benefit greatly if pulmonary function testing was used more consistently when diagnosing the condition. COPD is currently the third principal cause o...

  • New EU study highlights differing priorities in physician's therapy goals when treating advanced lung cancer patients

    Nov 11, 2016 Results from a survey analysing the prescribing behaviour of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been published in Clinical Lung Cancer. The research examined the primary therapy goal of physicians and their choice of treatment for patients...

  • St George’s NHS Foundation Trust to be placed in Special Measures

    Nov 02, 2016 St George's University Hospitals NHS Foundation Trust, which provides care to people at its St George's and Queen Mary's hospitals in London, is being placed in special measures after an inspection by the Care Quality Commission (CQC) back in June found it the trust to be lacking on a variety of...

  • CPIA Report – Medical Affairs

    Oct 27, 2016 Only Medics, part of the Clinical Professionals group, collaborate with Vacancysoft to create regular reports that provide a detailed analysis of vacancies across various sectors, countries and companies. This CPIA report features analysis and data from the Medical Affairs sector within the ph...

  • NHS England Offering £400k for Digital Mental Health Fund

    Oct 18, 2016 Digital tech companies can now compete for a share of £400,000 on offer from NHS England to help progress uptake of their products designed to improve mental health. The NHS England funded Digital Development Lab - run by mHabitat in partnership with MindTech and Social Spider - will prov...

  • Recent Study Finds UK Cancer Cases on the Rise

    Oct 12, 2016 A recent Cancer Research UK Study published in the British Journal of Cancer has found that half a million people will be diagnosed with cancer within the next 20 years if current trends continue. Currently over 352,000 people in the UK are diagnosed every year, but this is expected to exceed b...

  • NHS England has stated most CCG Cancer Services require improvement

    Oct 05, 2016 Ambitious goals set out by the Cancer Taskforce has highlighted that the majority of clinical commissioning groups (CCG) in England are required to improve their cancer services. If achieved, an extra 30,000 lives could be saved by the year 2020. With the aim of improving the standard of patient ca...

  • NICE publish recommendation of hypophosphatasia drug

    Sep 28, 2016 NICE has published further draft guidance as part of its highly specialised technologies programme recommending asfotase alfa (Strensiq, Alexion Pharma UK) for children with hypophosphatasia. A rare, and often fatal genetic condition. The drug is the first treatment to target the underlying cau...

  • New UK Cancer Drug Fund Marks Shift in Market Access Landscape

    Sep 22, 2016 The Recent unveiling of the new Cancer Drugs Fund (CDF) in the UK highlights a major shift within the market access landscape, although it has caused trepidation amongst pharma and patient groups, in addition to raising some difficult questions about HTA processes. The newly proposed CDF structure ...

  • AZ initiate trials for using diabetes drug in kidney disease and heart failure

    Sep 13, 2016 AstraZeneca has launched two new trials with its SGLT-2 inhibitor Forxiga with the aim of exploring its potential beyond the drug's approved diabetes indication. AZ have initiated two randomised, placebo-controlled Phase IIIb outcome trials assessing Forxiga in the management of chronic kidney dise...

  • Study Shows GSK’s Bexsero Halved UK Meningitis B Cases in First Year

    Sep 07, 2016 GlaxoSmithKline's meningitis B vaccine, Bexsero, has shown to have a dramatic impact on meningitis B cases within the UK, according to a real-world evidence study. Approximately a year ago the world’s first national meningitis B vaccination campaign was launched, after 10 months there ha...

  • Cancer Research UK Launches Pancreatic Cancer Trial

    Aug 30, 2016 Cancer Research UK has begun a first-of-its-kind clinical trial to exploring the possibility of making pancreatic cancer cells more responsive to chemotherapy and radiotherapy. The trial will treat pancreatic cancer patients where their tumours have grown too big for surgery but have not yet s...

  • NICE Recommend NHS funding for Pfizer’s Bosulif and Eli Lilly’s Alimta

    Aug 24, 2016 NICE has recommended regular National Health Service funding for two more drugs from the old Cancer Drugs Fund – Pfizer’s Bosulif and Eli Lilly’s Alimta. The National Institute for Health and Care Excellence’s final guidance decision enables Alimta maintenance treatment to b...

  • Clinical Professionals Group Post EU Referendum Statement

    Aug 09, 2016 On Thursday June 23rd 2016, tens of millions of people within the UK voted on whether we should remain within the EU. The following day it was announced that the UK will be set to leave the EU with the votes swaying 51.9% for leave and 48.1% for remain, with a 72.2% turnout. In light of the res...

  • Court Ruling – NHS to pay for Gilead Drug for HIV Prevention

    Aug 03, 2016 A court in England has recently ruled that NHS England can pay for Gilead’s Truvada for use in HIV prevention, after campaigners took legal action over the refusal to fund it. Earlier this summer NHS England had refused to pay for Truvada, saying that it was down to councils to fund prevent...

  • NICE recommends PTC Therapeutics Duchenne muscular dystrophy treatment

    Jul 20, 2016 PTC Therapeutics has announced that NICE has issued final guidance recommending Translarna for ambulatory patients aged five and over with nonsense mutation Duchenne muscular dystrophy in connection with a managed access agreement with NHS England. Duchenne muscular dystrophy, a rare genetic d...

  • Research Groups Unite to Create Collection of Accessible Cancer Models

    Jul 12, 2016 Four of the industry leading research groups in the EU have joined to launch an international project with the aim to set up a large, globally accessible, bank of new cancer cell culture models for future research. The National Cancer Institute (NCI), Cancer Research UK, the Wellcome Trust Sang...

  • Online access now available at majority of GP practices within England

    Jul 06, 2016 Official figures have shown that more than 95% of GP practices in England are set up to offer online access to GP records. Access to test results can now be viewed by over 55M patients on arrival to the practice, in addition they will be able to access key data such as diagnoses, immunisations ...

  • University Research into Cancer Genes Could Progress Personalised Treatments

    Jun 29, 2016 Research conducted by scientists and doctors at the University of Southampton and Royal Bournemouth Hospital, has identified a network of genes that are likely to be shared by all patients who have chronic lymphocytic leukaemia (CLL). The study has also identified gene networks that are associated ...

  • Takeda to Initiate World’s First Norovirus Vaccine Field Trial

    Jun 22, 2016   Takeda has initiated a clinical trial testing the potential of the world’s first experimental vaccine for norovirus, which is responsible for nearly three quarters of a billion illnesses and 219,000 deaths each year around the globe. The Phase IIb, double-blind, randomised, pla...

  • Jardiance Reduces Risk of Progressive Kidney Disease in Patients with Type 2 Diabetes

    Jun 14, 2016 New data showed Jardiance reduced the risk of new-onset or worsening kidney disease by 39% versus placebo when added to standard care in adults with type 2 diabetes with established cardiovascular disease. Boehringer Ingelheim and Lilly announced the findings at the American Diabetes Associati...

  • Merck says Phase III trials for Keytruda as treatment for Advanced Melanoma show better survival

    Jun 08, 2016 Merck & Co has stated that the late-stage trials for its immunotherapy Keytruda to treat advanced melanoma has showed over half of the patients were alive two years after treatment had first began. The data gathered was part of multiple study results for its immunotherapy Keytruda in sever...

  • Ryboquin Raises £1.3m for Cancer Drug Development

    Jun 01, 2016 A Scottish Borders-based pharmaceutical firm, Ryboquin has raised £1.3m towards cancer gene therapy drug development. The money will allow Ryboquin Ltd to take the product - named Ryboquin ECP-102 - one step closer to clinical trials. The firm, which has its headquarters in Selkirk, rais...

  • J+J Announce Collaboration to Create Personalised Healthcare Solutions with 3D Printing

    May 19, 2016   Today Johnson & Johnson announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The partnership will be focused on using 3D printing technologies to create better healthcare outcomes at a reduced cost. By working together, the companies plan t...

  • Pfizer to Test Cancer Immunotherapy Combination

    May 11, 2016 Pfizer is reportedly gearing up to test a combination of three cancer drugs in human trials next year. According to the Financial Times, the trial, which will be one of the first to test a trio of immunotherapies, will monitor the safety and efficacy of the combination in patients with solid ca...

  • Are You Paid Enough?

    Apr 26, 2016 In our 2016 Life Science Salary Survey, we have discovered that a staggering 49% of UK Pharmaceutical Physicians believe that their salary does not reflect their current career level. Although the majority believed otherwise, it still shows significant discord and lack of confidence in salaries with...

  • Three Million Patients Are Now Using Health Innovations under NHS Scheme

    Apr 19, 2016 Approximately 3 Million patients have been tapping into new apps, safety devices, online networks, and a variety of other new technologies and services during the tentative first nine months of a pioneering programme designed to introduce new innovations to the NHS. The NHS Innovation Accelerator p...

  • Only a Small Amount of COPD Patient May Benefit from Inhaled Corticosteroids

    Apr 14, 2016 Boehringer Ingelheim’s new publication (WISDOM) shows that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not benefit from the addition of ICS treatment. In WISDOM, for 80 percent of patients, the use of ICS on top of Spiriva and a LABA ...

  • CHMP recommends GSK Gene Therapy for ADA-SCID for EU Approval

    Apr 06, 2016 The EU's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of potentially the first corrective ex vivo gene therapy for children anywhere in the world. GlaxoSmithKline received the green light from the CHMP for Strimvelis as a treatment for the rare disease ADA-...

  • NHS England to fund HIV treatment Rezolsta

    Mar 30, 2016 NHS England will provide crucial funding for Janssen’s once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called Rezolsta. Rezolsta is indicated for use in combination with other antiretroviral medications for treating adults with HIV-1, whose virus does not...

  • Only Medics Celebrates Easter with Local Charities

    Mar 24, 2016 Only Medics as part of the Clinical Professionals Group have helped to raise £110 to buy Easter eggs for children at the Rainbow Trust and at Camp Mohawk! The Rainbow Trust is a children’s charity that was first established in 1986 that supports families who have a child aged 0-18 wh...

  • Scotland Unveils £100-million Cancer Strategy

    Mar 17, 2016 Scotland has unveiled a £100-million strategy to tackle cancer by improving prevention, detection, diagnosis, treatment and after care for those affected by the disease. The Scottish government has stated its strategy; “Beating Cancer: Ambition and Action”, which contains mor...

  • Three New Drugs Approved for Use on NHS Scotland

    Mar 09, 2016 Three new medicines have been granted approval by cost regulators for use on NHS Scotland. The new treatments will offer options to patients for breast cancer, prostate cancer and heart failure. The Scottish Medicines Consortium has now accepted use of Eisai’s Halaven (eribulin) for the t...

  • NHS to help design 10 'healthy new towns' to Tackle Challenges such as Obesity and Dementia

    Mar 03, 2016 NHS England will be helping to design 10 ‘healthy new towns’ across the country in collaboration with Public Health England, with the aim of developing new solutions to key healthcare challenges within the country such as obesity and dementia. The plan stipulates more than 76,000 n...

  • NICE Updates Guidance On Clot-Removing Procedure for Stroke Patients

    Feb 25, 2016     NICE have published updated guidance for the NHS on a procedure to treat patients who have had a stroke. The guidance concludes that the use of mechanical clot retrieval for removing a clot from a blocked brain artery in people who have had an acute ischaemic stroke is safe and effe...

  • NHS to Invest £1bn a Year with the Aim to Boost Mental Health Care

    Feb 17, 2016     NHS England will be investing an extra £1 billion a year in improving mental health services, in line with a wide-reaching set of recommendations made by the Mental Health Taskforce. The Taskforce has recently laid out its vision for how mental and physical health care can fin...

  • NICE State GPs should take Individual-Based Approach to Sun Exposure Advice

    Feb 10, 2016 New NICE guidelines state GPs should take an individual-based approach when offering advice about sun exposure and take into account a person’s behaviour and skin type. The guidelines, published today, focus on the dangers of excess sun exposure in people in high risk groups, such as chil...

  • NICE Increases Access to Ankylosing Spondylitis Therapy

    Feb 03, 2016 Cost regulators for the NHS England and Wales have expanded treatment options for patients with ankylosing spondylitis. NICE has now published guidelines recommending TNF-alpha inhibitors -adalimumab (AbbVie’s Humira), certolizumab pegol (UCB Pharma’s Cimzia), etanercept (Pfizer&rsq...

  • NHS Cancer Patients Gain Access to Four New Therapies

    Jan 27, 2016 NICE has issued final recommendations endorsing NHS use of new therapies for ovarian cancer, multiple myeloma and prostate cancer, although they have rejected one for gastric cancer. AstraZeneca’s Lynparza has won backing as a maintenance treatment for patients with relapsed platinum-sens...

  • NHS Screening Programmes will Adopt New Tests for Cervical and Bowel Cancer

    Jan 20, 2016 The NHS could soon start routinely offering a test for HPV instead of a cervical smear as the initial screening test for cervical cancer, after experts ruled the change in approach would help to pick up cancers more effectively. The National Screening Committee (NSC) has advised the screening progr...

  • NHS Check has Prevented 2,500 Cardiovascular Events, Study Finds

    Jan 15, 2016 An evaluation of the NHS Health Check - a national screening programme designed to measure people’s risk of cardiovascular disease – Queen Mary University has found that 2,500 heart attacks and strokes has been prevented. The findings, published in BMJ Open, have also shown that take-up...

  • Would you Like a Complimentary Copy of our 2016 Salary Survey?

    Jan 11, 2016 Only Medics, part of the Clinical Professionals Group, are delighted to announce that our 2016 Life Sciences Salary Survey is complete and available for delivery. Nine months in the making, the survey was launched with the aim to analyse industry salaries, coms/benefits for core roles throughout ...

  • Merry Christmas from Only Medics

    Dec 24, 2015 Only Medics will be closed from the afternoon of the 24th December 2015 until Friday 1st January 2016. Only Medics and the Clinical Professionals Group have had a very successful and eventful past 12 months: •    Record year for placements•    The introducti...

  • Pharma to Advance £200m to UK Government for 2016 Medicines Bill Funding

    Dec 22, 2015 New financial agreement with the UK government will see pharmaceutical companies bring forward payments of around £200 million to help pay for NHS patients’ medicines in 2016. The payments are part of the Pharmaceutical Price Regulation Scheme (PPRS) that has seen pharma pay back over &...

  • Women Missing out on Cardiac Rehabilitation

    Dec 16, 2015 A new report from the British Heart Foundation has found that over 24,000 female heart patients are missing out on vital rehabilitation, thereby putting thousands at greater risk from further heart attacks.The National Audit of Cardiac Rehabilitation, which is funded by the charity and hosted at the...

  • NICE green-lights use of innovative heart failure drug on the NHS

    Dec 11, 2015 GPs could soon be treating many heart failure patients with a completely new drug, under NICE draft plans for phasing out ACE inhibitors and angiotensin receptor blockers (ARBs). NICE experts have provisionally given the green light for the new drug, a combination of sacubitril and the ARB valsarta...

  • NICE Advocates Tailored Approach to Treating Diabetes

    Dec 04, 2015 NICE has published an update to its guideline on the treatment and management of type II diabetes, with a new focus on an individualised approach to secure the best possible outcome for patients. The previous version had come under fire for its emphasis on cost over care, with many experts voic...

  • ONLY MEDICS: Aftermath of the Physician to Pharma Event

    Nov 24, 2015 Only Medics held this year’s renowned Physician to Pharma event at the Hilton hotel in Reading on November 12th 2015. Physician to Pharma was created to help smooth the transition of non-industry medics into pharmaceutical roles, it offers unmatched career advice and access to existing member...

  • A Medics Route to the Pharmaceutical Industry

    Nov 10, 2015 Only Medics is a well-established specialist staffing company that focuses on the recruitment of physicians for the pharmaceutical industry, clinical research organisations, regulatory authorities and biotechnology companies. Only Medics not only recruits in the UK but also globally for both pe...

  • NHS could save millions with New Radiotherapy Regime for Prostate Cancer

    Nov 05, 2015 Recent findings from a major clinical trial presented at the NCRI Cancer Conference in Liverpool this week has suggested that the NHS could save millions by changing to a new radiotherapy regime targeted at patients with prostate cancer. According to the CHHiP study, led by researchers at the ...

  • NHS Research Activity on the Rise

    Oct 20, 2015 According to new data from The National Institute for Health Research (NIHR) and Clinical Research Network’s (CRN) annual league table, NHS England has achieved a significant increase in clinical research over the last year. The league table details the number of studies undertaken and the nu...

  • NHS England Newcomers to Help Drive Five-Year Plan

    Oct 13, 2015 NHS England has elected three new appointments to strengthen its work on primary care, drive improved cancer services, and to lead the commissioning of specialised hospital services. A move that chief executive Simon Steven says will help “turbo-charge” implementation of the Five Yea...

  • NHS Recommends MSD's skin cancer drug Keytruda

    Oct 06, 2015 A few patients with advanced skin cancer will now be able to get routine access to Merck, Sharp & Dohme’s immunotherapy Keytruda on the NHS in England and Wales, after cost regulators issued final guidance endorsing its use within a limited population. As expected, the NICE (National Inst...

  • UK Surgeons Carry out First Stem Cell Therapy for Wet AMD

    Sep 29, 2015 UK surgeons have carried out the first stem cell therapy designed to treat wet age-related macular degeneration, which will cure a cause of blindness within the elderly. The procedure marked the beginning of a ground-breaking trial that was investigating the safety and efficacy of transplanting...

  • NHS Atlas of Variation Report Shows Huge Gaps in Care Quality and Access

    Sep 17, 2015 Latest NHS Atlas of Variation report indentifies huge differences in access to health services and the quality of treatment across England. The report (compiled by Public Health England and NHS England) looked at the performance of all 211 clinical commissioning groups across the country, and ...

  • National Institute for Health and Care Excellence give approval for BI's lung-scarring drug, Ofev

    Sep 15, 2015 UK patients with idiopathic pulmonary fibrosis could soon get regular access to the first targeted therapy on the NHS in England and Wales, after cost regulators issued a preliminary green light for Boehringer Ingelheim’s Ofev. In draft guidance from Friday, NICE supports use of Ofev (ni...

  • Clinical Professionals’ Acquisition by CPL

    Sep 03, 2015 Yvette Cleland CEO of Clinical Professionals Ltd is delighted to announce its acquisition by Ireland’s leading employment services group, CPL Resources PLC. As Europe’s leading life science staffing company we strive to provide the highest quality service for both candidates and c...

  • Lilly and Boehringer to Launch Biosimilar Insulin in the UK

    Aug 26, 2015 Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar is a biosimilar of Sanofi’s insulin glargine product, Lantus, which achieved $8.43 billion in sales for Sanofi in 2014. Lilly and Boehringer’s diabetes alliance alre...

  • UK Paramedics Could be Drafted in to Help General Practice

    Aug 18, 2015 NHS England confirmed that it is currently running a consultation on whether some advanced-level paramedics should be given independent prescriber status, to give patients quicker access to treatment, but stressed there are no proposals for taking on routine GP appointments. Paramedic independent p...

  • Three New Drugs Green-Lighted for NHS Scotland

    Aug 12, 2015 Cost regulators for the NHS in Scotland have endorsed new medicines for the treatment of HIV, asthma and MRSA-related skin infections. The SMC (Scottish Medicines Consortium) put forward Janssen-Cilag’s Rezolsta (darunavir cobicistat) in combination with another antiretroviral as an option fo...

  • The World’s First 3D Printed Drug Approved

    Aug 09, 2015 In the past few years 3D printing has become the next big trend on the horizon and it has now turned its sights onto the pharmaceutical industry…A few days ago the FDA approved the world’s first 3D printed drug; Aprecia’s Spritam and will be used for treating epilepsy.One of the m...

  • Biogen enters strategic alliance to develop new Parkinson’s disease treatments

    Jul 28, 2015 Biogen has formed a strategic alliance with the Parkinson’s Institute and Clinical Center to improve understanding of the underlying biology of Parkinson’s disease (PD) and discover new tools and programs to accelerate research and development of new PD treatments. The deal will combine ...

  • MRC, GSK and UK Uni's Collab for Inflammatory Diseases Drug Development

    Jul 21, 2015 GlaxoSmithKline (GSK) and the UK's Medical Research Council (MRC) will be collaborating in an open innovation research initiative aiming to improve scientists’ understanding of inflammatory diseases. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will bring tog...

  • What impact do GPs think the new NHS cancer guide will have?

    Jul 15, 2015 Doctors are being told to extend cancer tests to half a million more patients a year under the new NHS guidelines. The guide – designed to be used by doctors and patients – signposts for the very first time the symptoms that could be indicative of one of 37 cancers. GPs can already reque...

  • New Test Could Predict Piologic Drug Failure in Patients with Arthritis

    Jul 07, 2015 A study conducted at the University of Manchester suggests it may be possible to predict which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them.  Biologics are given by injection and they work by stopping particular chemicals in the blood fro...

  • Doctors and Nurses Told to Admit Mistakes

    Jun 30, 2015 According to new guidelines, face-to-face explanations and apologies will need to be given to patients or close ones when things regarding their treatment and wellbeing go wrong. The guidance follows Sir Robert Francis’ call for a more open and transparent culture within healthcare in his repo...

  • Infants to be offered Meningitis B vaccines from September

    Jun 23, 2015 Guidance on vaccinating infants against meningitis B from September and students from August will be sent to GPs in England and Scotland. The announcement follows health secretary Jeremy Hunt’s deal with British vaccine manufacturer GSK in March in order to add MenB vaccine Bexsero to the chil...

  • NHS: £190m set aside for Hepatitis C

    Jun 17, 2015 The budget for HCV therapies will be increased from last year’s £40 million to £190 million says NHSE (NHS England). This will provide stop-gap access to drugs such as AbbVie's on Viekirax and Exviera to around 3,500 patients with cirrhosis. NHSE's Clinical Priorities Advisory Gro...

  • Teva $40 Billion Offer to Acquire Mylan

    Apr 21, 2015 Following weeks of speculation, Teva yesterday made a $40-billion-bid for Mylan NV. Teva has offered $82 per Mylan share in a 50/50 cash/stock transaction valued at just over $40 billion. However, the reaction so far to the news suggests that Teva would need to improve on their bid for it to be ac...

  • Johnson & Johnson Exceed Q1 Estimates

    Apr 14, 2015 Johnson & Johnson have announced positive results for the first quarter of 2015, beating earnings expectations. However, the company has been forced to lower their full-year expectations for 2015 from $6.12-$6.27 per share to $6.04-$6.19, as a result of exchange rates with a strong US dollar.&n...

  • Takeda Signs Oncology Biotech Deal

    Mar 24, 2015 Takeda has announced that they have signed a deal with ImmunoGen for two anticancer targets. Takeda signed the agreement with ImmunoGen through its subsidiary Millennium Pharmaceuticals. The agreement, which grants Takeda exclusive rights to use ImmunoGen's ADC technology for anticancer therapeuti...

  • Bristol-Myers Squibb Acquires Cancer Specialist, Flexus, for $800m

    Feb 24, 2015 Bristol-Myers Squibb have announced that they will be acquiring Flexus Biosciences in an agreement worth up to $1.25 billion. Flexus are a biotechnology company which specialises in the discovery, development, and commercialisation of small-molecule cancer immunotherapies targeting regulatory T cel...

  • Roche Acquires Signature Diagnostics

    Feb 10, 2015 Roche has today announced that they have acquired Germany’s Signature Diagnostics. Signature Diagnostics were a privately-held translational oncology and genomics company, based in Potsdam, Germany. The acquisition is the fifth deal that Roche has made within the past year, aimed at building...

  • Roche Report 2014 Results, Boosted by Breast Cancer Treatments

    Jan 28, 2015 Roche have today announced their 2014 results, with sales in 2014 growing 1% (5% at constant exchange rates) to 47.46 billion francs. However, net profit for the healthcare company fell 16% to 9.54 billion francs, hit by a one-time restructuring charge. Sales increased 4% (at constant exchange rat...

  • Only Medics Referral Scheme

    Jan 07, 2015 Only Medics, part of the Clinical Professionals Group, have launched a new online referral form, allowing people to easily refer a friend or colleague who may be looking for a new job within life sciences. The Clinical Professionals Group offers a generous referral scheme of £250 vouchers (or...

  • Only Medics Christmas 2014 Opening Hours

    Dec 17, 2014 Only Medics, part of the Clinical Professionals Group, will be closed from the afternoon of the 24th December 2014 until Friday 2nd January 2015. We would like to wish all our clients and candidates a very Merry Christmas and Happy New Year! The Clinical Professionals Group have had a very succe...

  • Physician2Pharma Event a Success

    Nov 27, 2014 Earlier this month Only Medics, part of the Clinical Professionals Group, held their annual Physician2Pharma recruitment event for NHS medics looking to transition into the pharmaceutical industry. The event was invite only and attended by 40 people comprising of hand picked GMC registered physicia...

  • AstraZeneca Confident of Reaching $45bn Sales by 2023

    Nov 18, 2014 AstraZeneca have confirmed that they remain confident of generating annual sales of over $45 billion by 2023. The increase is expected as a result of accelerating growth momentum from both AstraZeneca’s existing products and those currently awaiting market approval. Five current growth platf...

  • AstraZeneca Acquires Definiens

    Nov 04, 2014 AstraZeneca has announced that they are acquiring tissue sample specialist, Definiens, increasing their oncology efforts. AstraZeneca’s MedImmune unit is paying an initial $150 million, followed by additional predetermined milestone payments, to acquire Definiens.  AstraZeneca noted that...

  • Bristol-Myers Squibb Announce Positive Q3 Results

    Oct 27, 2014 Bristol-Myers Squibb have announced positive third quarter results for 2014, beating earlier forecasts after stronger-than-expected revenues for the period. The biopharmaceutical company posted earnings on Friday of $721 million, or $0.43 a share, an increase from earnings of $692 million, or $0.42...

  • UK Invests £230 million into Revolutionising Research

    Oct 22, 2014 A new initiative being led by the Medical Research Council (MRC) has been announced today involving more than £230 million being invested in a range of “revolutionary technologies” to identify the causes of diseases, such as cancer and dementia. The Clinical Research Infrastructur...

  • Roche Reports Positive Q3 2014 Results

    Oct 15, 2014 Roche has announced positive Q3 results for 2014, with pharmaceutical sales increasing by 4% in the third quarter to 9.13bn francs, while their diagnostics division grew by 7% to 2.65bn francs. The results were boosted by increased sales of Roche’s new breast cancer drugs, Perjeta and Kadcyla...

  • Chronic Heart Failure Drug Sales Expected to Increase

    Oct 09, 2014 New forecasts published by Decision Resources show an expected increase in the sales of medicines to treat chronic heart failure.  The forecasts show growth from around $2.9 billion in 2013 to an expected $8.9 billion in 2023. Growth in seven main markets (US, UK, France, Germany, Italy, Spain...

  • Merck KGaA Partners with ICR and Wellcome Trust to Develop Anti-Cancer Drugs

    Oct 06, 2014 Merck KGaA have today announced a new partnership with the Institute of Cancer Research (ICR) and the Wellcome Trust to develop cancer treatments. Merck KGaA’s Merck Serono unit will work with the UK organisations to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymer...

  • Cubist Pharmaceuticals Announce New Zurich Office

    Sep 21, 2014 Cubist Pharmaceuticals, who specialise in the development of antibiotics for infectious diseases, has announced the launch of their new international headquarters based in Zurich, Switzerland. The new office will expand Cubist’s presence outside of the US, allowing the company to reinforce th...

  • Bayer to Increase Pharmaceutical R&D Spend

    Sep 18, 2014 Bayer have announced additional details on the future of their pharmaceutical research and development business following the announcement earlier this week that they will be concentrating on their healthcare and crop science businesses going forward. The announcement confirmed Bayer plans to float...

  • Annual UK Dementia Costs Reaches £26 Billion

    Sep 09, 2014 A new report published by the Alzheimer’s Society has found that the cost of dementia in the UK has now surpassed £26 billion a year. The review by the London School of Economics and King's College London, of dementia across the UK, found that the bulk of the costs associated with demen...

  • Janssen’s Affiliate Cilag to Acquire Covagen

    Aug 25, 2014 Janssen affiliate’s Cilag GmbH International has announced that they will be acquiring Swiss biotech Covagen AG for an undisclosed sum. The purchase was finalised in a deal brokered by Johnson & Johnson Innovation Center in London. Covagen specialises in the development of multi-specific...

  • UK Death Rates for Breast, Bowel, Lung and Prostate Cancer Drop by 30%

    Aug 17, 2014 A new report released today by Cancer Research UK has shown that the death rates for breast, bowel, lung and prostate cancer in the UK have fallen by 30% in the last 20 years. The figures from Cancer Research UK show that breast cancer deaths have fallen by 38% since the early 1990s, while bowel ca...

  • Reckitt to Spinoff their Pharmaceutical Business

    Jul 27, 2014 Reckitt Benckiser have today announced that they are planning on separating their pharmaceutical business, as they continue to concentrate on consumer health and hygiene. The process to separate RB Pharmaceuticals to be a separate UK listing is expected to occur within the next 12 months. The deci...

  • Biogen Idec Posts Positive Q2 2014 Results

    Jul 23, 2014 Biogen Idec yesterday announced positive second-quarter financial results for 2014. The results were boosted by sales of their oral multiple sclerosis drug, Tecfidera, which increased net profits by 46%, comfortably passing analyst forecasts. Earnings for Biogen reached $714.5 million, while reven...

  • Shire Prepared to Recommend AbbVie's £31 Billion Offer

    Jul 13, 2014 Shire have confirmed that they are willing to recommend the takeover bid offer by AbbVie, after the company increased their offer to £53.20 a share. The updated offer submitted on Sunday follows four previous unsuccessful bids by AbbVie to acquire Shire. Shire confirmed that the new bid...

  • ProStrakan Acquires Archimedes for £230 Million

    Jul 10, 2014 ProStrakan, which is owned by Japan’s Kyowa Hakko Kirin, has announced that they will be acquiring UK cancer pain specialist, Archimedes Pharma, for £230 million in cash. ProStrakan, which is based in Scotland, is purchasing Reading-based Archimedes from Denmark’s Novo Nordisk Fou...

  • Medtronic Acquires Covidien in $42.9 Billion Deal

    Jun 15, 2014 US medtech company, Medtronic have confirmed the purchase of Ireland’s Covidien for $42.9 billion in cash and stock. Medtronic is the second-largest maker of medical devices, and once the transaction has been completed, the company noted that will have “significantly advanced” the...

  • Positive Clinical Trial Results for Bristol-Myers Squibb’s Immunotherapy Combo

    Jun 02, 2014 Results of a clinical trial combining Bristol-Myers Squibb’s Yervoy and Nivolumab show an exceptional improvement in tumour regression and overall survival rate for patients with advanced melanoma. Mario Sznol of Yale University School of Medicine, reporting the results of the early-stage stu...

  • Bristol-Myers Squibb Announce Oncology Research Collaborations with CytomX and Incyte

    May 27, 2014 Bristol-Myers Squibb (B-MS) yesterday announced a worldwide research partnership and license agreement with CytomX. The collaboration plans to discover, develop and commercialise novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody Platform. Probodies a...

  • Valeant Pharmaceuticals Plan Improved Allergan Bid

    May 13, 2014 Valeant yesterday confirmed that they are planning on making an improved, bigger offer for Allergan after their initial unsolicited $46 billion takeover offer was rejected. US pharmaceutical company, Allergan, who are best-known for their Botox, rejected Valeant and investor Bill Ackman’s Per...

  • Merck & Co Announce Increased Profit for Q1

    Apr 29, 2014 Merck & Co’s have released their Q1 results for 2014, showing an increase in profit, despite being hindered by unfavourable exchange rates and patents expiring. The healthcare company announced net income of $1.70 billion, an increase from the $1.59 billion net income of Merck & Co&rs...

  • Novartis, GSK and Eli Lilly Agree Multi-Billion Dollar Restructuring Deals

    Apr 21, 2014 Novartis and GlaxoSmithKline (GSK) have announced restructuring deals worth billions of dollars, as they aim to concentrate on specialist areas of their business going forward. Within the agreement, GSK will sell their cancer portfolio to Novartis for $14.5 billion upfront and $1.5 billion in miles...

  • Abbott Announces 2014 Q1 Results

    Apr 16, 2014 Abbott yesterday revealed financial results for the first quarter of 2014.  The company announced worldwide sales of $5.2 billion. Excluding foreign exchange, the company-wide results included an increase of 0.5% on an operational basis and a decrease of 2.5% on a reported basis. Internationa...

  • Novartis Investigate Science Park for Horsham Site Future

    Apr 13, 2014 Following the announcement earlier this year that Novartis would be closing their Horsham site, the pharmaceutical company have confirmed that they have hired PharmaVentures to investigate future options for the site. PharmaVentures has been appointed to provide advice on the feasibility of reusing...

  • Meda Rejects Mylan Takeover Bid

    Apr 06, 2014 Swedish drugmaker, Meda, have confirmed that they have rejected a takeover bid from US generics major, Mylan. Shares in Meda, which markets specialty treatments, over-the-counter products and branded generics, were frozen after a report from the Financial Times noted that Mylan was planning to subm...

  • Pancreatic Cancer Global Market Expected to Hit $1.6 Billion by 2017

    Apr 02, 2014 Sales predictions released by GlobalData claim that the global pancreatic cancer market is set to hit $1.6bn by 2017 as a result of rapid expansion, mainly driven by Celgene’s Abraxane. The prediction is a strong endorsement of Abraxane, which has been approved by both the US and European reg...

  • Celgene Partners with Abide Therapeutics

    Mar 03, 2014 Abide Therapeutics and Celgene have announced that they will be collaborating to discover and develop drugs in inflammation and immunology. As part of the terms of the partnership, Celgene has paid an upfront fee, reported to be $50 million, and will obtain a small equity stake in Abide Therapeutic...

  • Novartis Announces Closure of Horsham Site

    Feb 27, 2014 Novartis yesterday confirmed that they will be closing all operations at their Horsham site later this year, putting nearly 400 jobs at risk. The Swiss pharmaceutical organisation initially announced in November that they were considering the site’s closure as part of their global review of R...

  • New Forecasts Predict 3.8% Growth of Type 2 Diabetes’ European Sales

    Feb 17, 2014 According to new forecasts by Frost & Sullivan, the European market for type 2 diabetes drug treatments is set to grow 3.8% yearly, from a value of 9.50 billion euros in 2009 to 15.46 billion euros in 2017. More than 55 million people in Europe were diagnosed with diabetes in 2012, and this fig...

  • AbbVie Reports Drop in Sales

    Feb 03, 2014 Generic competition and foreign exchange rate has resulted in AbbVie reporting a drop in fourth-quarter sales, however their anti-inflammatory blockbuster Humira continues to soar. The company announced a net income of $1.13 billion, down 27%, while fourth quarter revenues dropped slightly to $5.11...

  • Pfizer Announce Solid Q4 Results

    Jan 29, 2014 Pfizer yesterday revealed a solid set of fourth-quarter results for 2013, with sales driven by their oncology unit, Lyrica and Enbrel. Net income for the quarter was $2.57 billion, a decrease of 59% on Q4 2012 (which included profits from the sale of their nutritional products business).  Grou...

  • AstraZeneca Partners with Immunocore

    Jan 08, 2014 The day after announcing a partnership with UK’s Horizon Discovery, AstraZeneca have announced another oncology partnership with Immunocore, a UK biotechnology company. The agreement with Immunocore focuses around Immunocore’s ImmTAC technology.  The technology has created a platfo...

  • 2014 Pharmaceutical Salary Survey Results

    Jan 07, 2014 Would you like to know how your salary compares to other employees in similar physician jobs? The results of The Clinical Professionals Group’s 2014 European Pharmaceutical Salary Survey are now available.  If you would like a free salary survey results book, contact Daniel Patterson or ...

  • Only Medics’ 2013 Christmas Opening Hours

    Dec 20, 2013 Only Medics, part of The Clinical Professionals Group, will be closed from the afternoon of Christmas Eve until Thursday 2nd January 2014.This year has been a very successful year for Only Medics, and we would like to take this opportunity to thank all of our clients and candidates, and wish you a v...

  • GSK Invests £25 Million into their Montrose, Scotland Facility

    Nov 26, 2013 GlaxoSmithKline (GSK) have announced that they will invest £25 million to bring production of ingredients for four new pharmaceutical products to their site in Montrose, Scotland. The investment is expected to create 25 new jobs for process technicians, engineers and chemists, increasing the ...

  • DSM Sells Pharmaceutical Division in $2.60 Billion Agreement

    Nov 20, 2013 The Netherlands’ Royal DSM have announced that they have sold their pharmaceutical unit to the US private equity firm, JLL Partners, as part of an agreement worth around $2.60 billion. They plan to set up a new, as-yet-unnamed, organisation that will combine the DSM Pharmaceutical Products (D...

  • Merck Revenues Fall in Quarter 3

    Oct 29, 2013 Merck & Co have seen revenues drop by 4 per cent in their third quarter, as their diabetes blockbuster, Januvia, continued to show signs of weakness in the US. Sales were reported to be $11 billion, with Merck’s DPP-4 inhibitor Januvia (sitagliptin) down 5% to $927 million.  Line ext...

  • Eli Lilly Announces Strong Q3 2013

    Oct 23, 2013 Eli Lilly have revealed a positive set of financials for their third quarter of 2013, which was aided by cost-cutting and continued strong sales of Cymbalta. Net income dropped by 9% to $1.20 billion, although it is worth noting that Eli Lilly’s results from Q3 of 2012 included an early payme...

  • Clinical Professionals Group Raise Over £200 for Breast Cancer Care

    Oct 21, 2013 The Clinical Professionals Group, which includes the team at Only Medics, raised over £200 for Breast Cancer Care on Friday 18th October, as part of Breast Cancer Awareness Month. The offices took part in a variety of ‘pink’ themed activities throughout the day, including a pink t...

  • Roche Announces Positive Q3 Results

    Oct 16, 2013 Roche have revealed positive financial results for the third quarter, strengthened by the sustained growth of their cancer drugs. Earlier today Roche announced that sales reached 11.57 billion Swiss francs, an increase of 8%, while their pharmaceutical revenue grew by 9% to 9.03 billion Swiss franc...

  • NHS Professionals Lack the Managerial Skills Needed for the Pharma Industry

    Oct 15, 2013 Many NHS doctors who wish to move into the pharmaceutical industry do not have a good enough understanding of the skills needed in a corporate culture. This was one of the findings of a think tank hosted by the Only Medics team. As it currently stands, less than 10% of NHS budgets are spent on deve...

  • Janssen Pharmaceuticals Acquire GSK Antiviral

    Oct 08, 2013 Johnson & Johnson’s Janssen Pharmaceuticals has acquired an investigational antiviral from GlaxoSmithKline (GSK) with the aim to develop an oral regimen for the treatment of hepatitis C (HCV). The pharmaceutical company has paid to obtain access to the NS5a replication complex inhibitor G...

  • Only Medics’ Physician to Pharma Success

    Sep 29, 2013 Only Medics, part of the Clinical Professionals Group, held a Physicians to Pharma event last Thursday, aimed to help medics who are looking to transition into the pharmaceutical industry. The event was invite only, and was attended by a select number of medics, in addition to a range of industry p...

  • AbbVie and Galapagos Sign $405 Million Agreement

    Sep 24, 2013 After recently signing an anti-inflammatory deal with Ablynx, AbbVie has now announced a new agreement with Galapagos in cystic fibrosis. Specifically, the organisations have confirmed that they will contribute technologies and resources to develop oral drugs that address the main mutations in cyst...

  • Physicians 2 Pharma Workshop

    Sep 22, 2013 Only Medics will be hosting a day of workshops for medics looking to transition to the pharmaceutical industry. The workshop will take place on Thursday 26th September in Reading, UK.  Attendance to the workshop is by invitation only. In addition to medics, the workshop will be attended by in...

  • AstraZeneca Partners with Merck & Co

    Sep 10, 2013 AstraZeneca have announced that they have licensed a drug which is currently in mid-stage clinical studies for ovarian cancer from Merck & Co. The agreement revolves around MK-1775, an oral small molecule inhibitor of WEE1 kinase, a cell cycle checkpoint protein regulator. Preclinical results ...

  • Otsuka Pharmaceutical to Acquire Astex

    Sep 04, 2013 Japan’s Otsuka has agreed to purchase cancer specialist, Astex Pharmaceuticals, in a deal which is valued at $886 million. Otsuka will obtain the remaining shares of Astex for $8.50 per share in cash, signifying a 48% premium to the average closing stock price for the prior 30-day period. On...

  • Incyte Shares Jump, After Positive Phase II Results for Jakafi

    Aug 21, 2013 Shares in Incyte increased by almost 34% yesterday after the company announced promising mid-stage data for their pancreatic cancer therapy, Jakafi. Positive results from a Phase II clinical trial showed that the JAK inhibitor, Jakafi (ruxolitinib), when used in combination with Roche’s Xelod...

  • Amgen Finalises Agreement With Servier

    Aug 13, 2013 Amgen have confirmed a new partnership with Servier to boost the pipelines of both businesses. The waiting period to let any antitrust concerns to arise has now passed, meaning the two companies can advance with the agreement. The deal will provide Amgen with rights in the US to Servier’s he...

  • Novo Nordisk Post Strong Q2 Results

    Aug 07, 2013 Novo Nordisk has announced another strong set of results, aided by strong sales of their diabetes drug, Victoza. The company’s net profit for the second quarter increased by 26% to 6.73 billion Danish kroner (equal to roughly $1.20 billion), while sales grew 10% to 21.38 billion kroner. The ...

  • Icon Posts Strong Quarter 2 Results

    Jul 29, 2013 Icon have announced that they have reviewed their guidance for revenues and earnings per share in fiscal year (FY) 2013 after posting another strong financial quarter. Earlier this week, Icon reported net revenues for their second quarter of US $334.2 million, an increase of 20.6% year on year, com...

  • Eli Lilly Reveals Strong Q2 Results

    Jul 24, 2013 Eli Lilly yesterday posted a strong set of financials for the second quarter of 2013, and announced that they would be raising their forecast for the full-year.  The Q2 results were aided by cost-cutting and strong sales of their blockbuster drug, Cymbalta. Net income soared by 36% to $1.25 bi...

  • J&J Report Strong Second Quarter Results

    Jul 16, 2013 Johnson & Johnson have reported strong results for their second quarter of 2013, with an 8.5% increase in sales.  The increase was aided by robust results from their prostate cancer drug, Zytiga. Net income reached $3.83 billion, a major increase from the $1.41 billion from the previous ye...

  • AstraZeneca and Roche to share early clinical trial data

    Jun 25, 2013 AstraZeneca and Roche have initiated a new medicinal chemistry data-sharing consortium to accelerate drug discovery in a smarter way. The companies say they will share “a specific type of early research data related to drug design, which could further accelerate the discovery of high quality ...

  • AstraZeneca announces new Cambridge Biomedical Campus

    Jun 18, 2013 Pharmaceutical giant AstraZeneca has announced it is setting up its new global headquarters, just south of Cambridge. The £330million research and development site will employ a skilled workforce of 2,000 people and will open by 2016. Research and Development will cease at Alderley Park in Ch...

  • If 8 areas of NHS activity were improved then vast amounts of money for CCGS could be saved

    Jun 12, 2013 If the National Health Service improved just 8 areas of their activity then 212 of England’s Clinical Commissioning Groups (CCGs) would save more than £1.6 billion. Statistics were analysed in research by consultancy MedeAnalytics. This covers all patient-level activity and associat...

  • Diabetes UK and Tesco Diets team up to raise awareness for healthy eating

    Jun 05, 2013 The major supermarket Tesco is forming an alliance with the charity Diabetes UK, to raise £10 million to create healthier communities to help those affected by or at risk of Diabetes. This alliance is recognising their shared views and opinions which have a common aim to help those affe...

  • Only Medics London office move to Bouverie Street

    May 23, 2013 Only Medics London office move to Bouverie StreetOn Friday May 24th, our London office will be moving from its current location in its offices in Quantum House, to 11-12 Bouverie Street. This move will more than double the office space from 700sq ft, to a new much bigger environment of 1,600sq ft &n...

  • Icon Release Strong Q1 Results

    Apr 29, 2013 Icon continued their run of solid quarterly results, reporting an operating income of US $23.0 million, an increase of 96.0% year on year.  Net revenues were also higher, at US $316.8 million. The income total included reorganisation, and other items amounting to US $4.41 million.  Withou...

  • Royalty Pharma’s Offer Rejected by Elan

    Apr 22, 2013 Elan Corp have confirmed that they have declined Royalty Pharma’s $11.25 per share acquisition bid, adding that the bid does not come near to what the drug maker is worth. Last week, Royalty decreased their bid from a previous offer which could have reached as high as $12, depending upon the ...

  • Royalty Increases Pressure on Elan with Superior Offer

    Apr 15, 2013 Royalty Pharma have increased their bid to acquire Elan Corp, in a move that values the Irish drug maker to up to $7.30 billion. After being asked by the Irish Takeover Panel to make a tangible offer by May 10th or abandon their plans to buy Elan, Royalty has made what they describe as a “fir...

  • European Pharmaceutical 2013 Salary Survey

    Apr 10, 2013 Do you earn the correct amount? As part of the Clinical Professionals Group, Only Medics are launching a European salary survey to determine the salary and benefits for European pharmaceutical physicians. The salary survey consists of questions concerning your career and how satisfied you are with...

  • AstraZeneca Acquires AlphaCore Pharma

    Apr 02, 2013 AstraZeneca have today announced that they are expanding their cardiovascular and metabolic disease pipeline with the acquisition of AlphaCore Pharma. AlphaCore are a Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase...

  • Cancer Research Technology, the Institute of Cancer Research and Janssen Partner for Myeloma Drug

    Mar 21, 2013 Cancer Research Technology (CRT) and the Institute of Cancer Research (ICR) announced earlier today that they have partnered with Johnson & Johnson unit, Janssen Biotech, in an agreement to discover a potential new drug for the blood cancer, multiple myeloma. The partnership is aiming to identi...

  • Drug Prices Could be Cheaper, Claims GSK Chief

    Mar 18, 2013 Prices of medicines should be lower and the high cost of research is a myth, according to GlaxoSmithKline’s boss Sir Andrew Witty. The pharmaceutical industry should be able to charge less for new drugs in the future by passing on efficiencies within R&D to their customers, according to t...

  • Only Medics to Attend DGPharMed 2013

    Mar 12, 2013 Only Medics will be attending DGPharMed’s annual conference at the Hotel Concorde, Berlin, Germany on the 14th and 15th March 2012. 2013 sees the 29th year of the annual conference by the German Society of Pharmaceutical Medicine. The conference starts at 9:20am, and finishes the following d...

  • Only Medics Relocate to New UK Office!

    Mar 11, 2013 As part of our continued expansion, Only Medics have relocated to a new larger UK office, having outgrown our previous office. The new office is over double the size of the previous UK office, allowing Only Medics to continue growing to fit your future needs. Our new office is located at: 3rd F...

  • Only Medics to Attend the 2013 BrAPP Conference

    Mar 01, 2013 Only Medics will be attending this year’s BrAPP Annual Symposium on 7th March 2013 in Royal College of Pathologists. The conference will start at 9am, and will conclude at 5pm with the BrAPP AGM for BrAPP members. The conference offers attendees the chance to opportunity to network with fell...

  • Warner Chilcott Q4 Net Income Increases 37.8%

    Feb 25, 2013 Warner Chilcott has announced that their fourth-quarter net income grew 37.8%, although pharmaceutical sales were hit by the impact of generic competition for their osteoporosis drug, Actonel. The organisation’s net income increased to $124 million, or 49 cents per share, up from $90 million,...

  • CROMSOURCE Expands in Poland

    Feb 20, 2013 CROMSOURCE, which was formed roughly two years ago as a result of the acquisition of MSOURCE by CROM, has combined it’s presence in Poland with a new office in Warsaw. When CROM acquired MSOURCE, the latter contract research organisation (CRO) had been internationally active since 1994. Dr O...

  • Roche and Chiasma Sign $585 Million Deal

    Feb 18, 2013 Roche has teamed up with Chiasma to develop and market Octreolin, Chiasma’s investigational treatment for growth hormone disorders. Octreolin is oral form of the peptide octreotide, a somatostatin analogue which is currently only commercially available by injection and is marketed by Novartis...

  • Tivozanib Matches Nexavar on Cancer Survival Rate

    Feb 14, 2013 Astellas and Aveo Pharmaceuticals have announced that the overall survival (OS) data for their kidney cancer drug, tivozanib, which demonstrates that it matches a key competitor. Two-year data from the TIVO-1 clinical study shows that there is no statistically significant difference in the overall ...

  • Sanofi Earnings Knocked by Generics

    Feb 07, 2013 Sanofi’s fourth quarter earnings have been hit by generics, although the majority of the patent cliff is now behind the French drugmaker, who anticipate a return to growth in the second half of 2013. Business net income, which excludes items, dropped 27.1% to 1.57 billion euros (at constant e...

  • Takeda Posts Q3 Financials, Boosted by Nesina and Pantoprazole Sales

    Feb 05, 2013 Takeda Pharmaceuticals have revealed reasonable financial results for the first nine months of their fiscal year, regardless of the major drop in sales of their diabetes drug, Actos. Japan’s largest drugmaker’s net income for the April-December period dropped 13.5% to 138.91 billion (ar...

  • Pfizer Release Q4 Financial and May Consider Splitting Their Drugs Unit

    Jan 30, 2013 Pfizer have released a reasonable set of financials despite the effects of generic competition to their cholesterol blockbuster drug, Lipitor. Fourth-quarter net income soared to $6.32 billion, up from $1.44 billion in the like-for-like quarter of the previous year.  The net income was boosted...

  • Watson Pharmaceuticals Renamed to Actavis and Announce Growth Strategy

    Jan 28, 2013 Watson Pharmaceuticals, the third-biggest generics drugmaker, have changed their name to Actavis and set out their growth plans. The company initially revealed intentions to change their name last year, succeeding the acquisition of the Actavis Group. The company has begun a multi-year rebranding ...

  • Allergan Purchases MAP Pharmaceuticals for $958m

    Jan 24, 2013 Allergan have agreed to pay $25 per share in a bid to purchase Mountain View's neurology group MAP Pharmaceuticals. The per share cash offer signifies a 60% premium over MAP’s closing stock price on January 22nd, and is equal to roughly $958 million. The merger agreement, which is expected t...

  • Johnson & Johnson’s Profits Boosted by Pharmaceutical Division

    Jan 23, 2013 Johnson & Johnson have announced an 8% rise in sales for their fourth quarter, aided by strong results from their pharmaceutical division. The group net income for the quarter was $2.57 billion, in comparison to $218 million in the fourth quarter of the previous year, when net income was affect...

  • Scotland Unveils £21m Fund for Rare Diseases

    Jan 16, 2013 A £21 million fund will been made available to pay for rare orphan drugs that are not currently recommended by the Scotland’s regulatory watchdog, the Scottish Medicines Consortium (SMC). The fund will launch in March, and run until April 2014.  It will help cover successful new In...

  • Amgen Partners with BIND in $180 Million Agreement

    Jan 09, 2013 Amgen has joined up with Bind Biosciences to develop a kinase inhibitor nanomedicine for treating a variety of solid tumours. The agreement provides the US biotech major with access to the technology at BIND, who has developed “a new class of highly selective targeted and programmable therape...

  • Ulcerative Colitis Drug Market to Reach $3.7 Billion by 2021

    Jan 03, 2013 Sales of medication to treat ulcerative colitis in seven key markets are expected to double over the next decade, reaching $3.7 billion by 2021, according new research. The rapid growth will be largely driven by two premium-priced tumour necrosis factor-alpha (TNF-alpha) inhibitors - Abbott/Eisai's...

  • Merry Christmas from Only Medics!

    Dec 24, 2012 We would like to wish all our clients and candidates a very merry Christmas and a happy new year!  Thank you for your business in 2012.  We look forward to working with you in 2013! Only Medics will be closed from the afternoon of the 24th December 2012 until the 2nd Janua...

  • Study Finds Antibiotics Ineffective for Coughs

    Dec 20, 2012 A recent study has found that the use of antibiotics to treat persistent coughs (not caused by pneumonia) is ineffective. The European study involved 2,061 patients with acute lower-respiratory-tract infections where pneumonia was not suspected, and the patients were randomised to receive either am...

  • ACM Global Expand EU Lab Facilities

    Dec 04, 2012 ACM Global Central Laboratory, the US-headquartered laboratory testing operation that raised its European profile in March 2009 by acquiring Pivotal Laboratories, have relocated their European laboratory to a bigger facility in York’s Hospital Fields Road. ACM Global confirmed that they have ...

  • GW Pharmaceuticals Announces Mixed Results

    Nov 29, 2012 GW Pharma has released mixed results for the year, with sales rising and profits decreasing, but the company continues to demonstrate potential in their R&D pipeline with inspiring data for a mid-stage, cannaboid-based diabetes drug. The organisation saw their sales for the year ending Sept...

  • Hunt Addresses ‘Overstretched’ GPs and Priorities for Change

    Nov 27, 2012 In his initial speech to primary care chiefs as Secretary of State for Health, Jeremy Hunt stressed his confidence in enlisting GPs at the centre of the new commissioning system, even though he acknowledged that GPs are being ‘overstretched’ already. Hunt informed delegates at the NHS A...

  • Bayer Withdraws Schiff Bidding Interest

    Nov 21, 2012 Bayer have declared that they are not going to follow plans to purchase American vitamins company, Schiff Nutrition International, four days after their $1.20 billion offer was beaten by Reckitt Benckiser. Roughly three weeks ago, Bayer announced a bid of $34 per share to acquire Schiff, but Reckit...

  • NHS hospital prescribing costs remain high

    Nov 15, 2012 New and expensive treatments are continuing to drive up NHS prescribing costs in England’s hospitals. This is according to a new IMS Health report, commissioned by the NHS, which found that hospital prescribing costs in England increased by 6.9% in 2011, far outstripping the 1.9% growth se...

  • Cancer Costs the UK £15.8 Billion per Year

    Nov 08, 2012 New research presented yesterday, claims that the total yearly price tag of all cancers to the UK economy is currently £15.8 billion, of which lung cancer accounts for £2.4 billion – far greater than any other type of the disease. The results of the research highlight the on-going...

  • Novo Nordisk Q3 Net Profit Grows 26%

    Nov 01, 2012 Novo Nordisk revealed more healthy sales figures yesterday for their third quarter results, aided by solid sales of their diabetes drug, Victoza, and its modern insulins. The company announced an 18% growth in sales to a total of 57.1 billion Danish kroner ($9.9 billion).  Operating profit inc...

  • NHS Satisfaction Decreases Amid Reforms and Cuts

    Oct 30, 2012 The reform of the National Health Service (NHS), alongside large funding cuts, is reducing people’s satisfaction with the NHS. This is according to the findings from the NHS Spring Public Perceptions of the NHS Tracker Survey, which was published on the weekend. The survey was led by the Ips...

  • AstraZeneca Announce 15% Sales Drop

    Oct 25, 2012 AstraZeneca have announced a dip of 15% for their Q3 sales, mainly as a result of the loss of exclusivity on several key brands, and costs relating to the disposal of their former Astra Tech and Aptium Oncology units. The Anglo-Swedish organisation’s revenue fell to $6.8 million in comparison...

  • UK Doctors To Have Regular Revalidation Assessments

    Oct 18, 2012 Jeremy Hunt announced today that UK doctors are to become the first in the world to have to take regular assessments to ensure they are fit for practise. The procedure, known as revalidation, will mean that British doctors will have regular assessments to confirm that their training and expertise a...

  • Depression Up 11.5% Over 3 Years

    Oct 17, 2012 The number of people suffering from depression in England has grown by almost half a million in just three years, according to a new report by SSentif Intelligence. Analysing the data from the NHS Quality Outcomes Framework, the group discovered that the number of registered patients with depressio...

  • Collaboration Best for Stretched NHS Budgets

    Oct 14, 2012 The Association of the British Pharmaceutical Industry (ABPI) head has noted that he understands that the UK National Health Service must save money, but wishes to create new partnerships to help this happen. Stephen Whitehead, chief executive of the ABPI, writing in the Guardian’s profession...

  • HRT Reduces Heart Attack Risk

    Oct 10, 2012 The dispute around the safety and benefits of taking HRT (hormone replace therapy) has taken another turn, after a study found that long-term use of the therapy considerably reduced heart attacks and heart failure, without raising the danger of cancer, blood clots or stroke. In the study, which was...

  • £200 Million Funding Increase for UK Scientific Research

    Oct 08, 2012 The UK government yesterday announced that they are contributing an additional £200 million to the Research Partnership Investment Fund to boost scientific research. As a result of the government support increasing to £300 million, the total investment is estimated to be a minimum of &p...

  • Rare Diseases Neglected and Misdiagnosed by NHS

    Oct 03, 2012 One in 17 people will be affected by a rare medical condition, but these conditions are too often neglected by the NHS, according to a recent report titled ‘Forgotten Conditions: misdiagnosed and unsupported, how patients are being let down’. This results in lower life quality for indiv...

  • Cancer Drugs Fund Opposed by British Public, Study Suggests

    Sep 30, 2012 A new study by the University of Bangor in North Wales has found that the British public do not support England’s Cancer Drugs Fund. The study asked over 4,000 people across England, Wales and Scotland if the NHS should pay extra for cancer drugs in comparison to medication for equally seriou...

  • Progenics Makes Further Job Cuts

    Sep 23, 2012 Progenics Pharmaceuticals are laying off more than a quarter of their workforce after failing to gain extended approval for their constipation drug, Relistor. The organisation noted that they are ending several early-stage research projects in order to concentrate on their cancer programmes, in par...

  • J&J Resolves ADHD Lawsuit with Impax Labs and Teva

    Sep 16, 2012 Johnson & Johnson (J&J) have established a new deal to settle a patent disagreement regarding their attention-deficit hyperactivity disorder (ADHD) drug, Concerta. Impax Laboratories and partner Teva Pharmaceutical Industries launched a lawsuit against Johnson & Johnson’s Janssen ...

  • Value-Based Pricing Discussions Passed to Jeremy Hunt

    Sep 05, 2012 The new UK health secretary Jeremy Hunt will be thrown into the deep end this month as he heads straight into negotiations over value-based pricing (VBT). Andrew Lansley, who was both the designer and lead for the value-based pricing discussions, was removed from the post of health secretary on Tue...

  • Agennix Cuts 55% of Jobs

    Aug 27, 2012 After the failure of their experimental lung cancer drug, talactoferrin, in a late-stage clinical trial, Germany's Agennix announced on Friday that they are reducing their workforce by roughly 55%. The restructuring plan will result in 37 jobs being lost and the firm's Houston, USA site being close...

  • Financial Feasibility of Orphan Drugs Confirmed by Study

    Aug 22, 2012 Drugs developed to treat rare diseases have the potential to produce as much lifetime revenue as medication used for more common health conditions, according to a study published by Thomson Reuters yesterday. The report compared the total value of orphan drugs from 1990 to 2030 and found that gover...

  • Competition Warning for Eight NHS Trusts

    Aug 20, 2012 Eight NHS hospital trusts have provided guarantees to the Office of Fair Trading (OFT) that they will stop exchanging commercially-sensitive information about their Private Patient Unit (PPU) prices, and ensure that they conform to competition law. The Office of Fair Trading confronted members of t...

  • AstraZeneca Teams With Regulus' MicroRNA Therapeutics

    Aug 14, 2012 AstraZeneca has announced that they have entered into a strategic partnership with US biopharmaceutical group Regulus Therapeutics to discover, develop, and commercialise microRNA therapeutics. The Anglo-Swedish drug giant has agreed to pay $28 million, which includes an equity investment and an up...

  • Elan Separates Discovery Activities into Neotope

    Aug 12, 2012 Elan today has announced that they have decided to spin off of their discovery science and Neotope Biosciences divisions into a separate business entity “to create two independent, highly focused, public companies.” After the separation, Elan will hold three key assets: the multiple scl...

  • UK Branded Drug Pricing Arrangements from 2014

    Aug 07, 2012 The UK department of health and the ABPI (Association of the British Pharmaceutical Industry) have set the groundwork for discussions over the new pricing structure for medicines in the UK, which will come into force in 2014 after the current Pharmaceutical Price Regulation Scheme (PPRS) scheme fini...

  • Teva Profits Increased by US Generic Sales

    Aug 02, 2012 Teva Pharmaceutical Industries announced solid financials for the second quarter of 2012, improved by sales of their multiple sclerosis drug Copaxone, sturdy generics growth in the US and the contribution of Cephalon’s products. Net income increased by 50% to $863 billion, while sales grew 19...

  • Delay to Personal Health Budgets Called for by RCGP

    Jul 25, 2012 The Royal College of General Practitioners (RCGP) is calling for the brakes to be put on the scheduled release of personal healthcare budgets, as although they back the aim of the project, they still have apprehensions about the execution and potential for inequalities. Pilot schemes comprising of ...

  • GPs Account for Under Half of CCG Board Members

    Jul 23, 2012 GPs account for less than half of the available leadership roles in the emerging clinical commissioning groups (CCG) across England, igniting concerns that doctors are being pushed aside from the decision-making procedure on which services to offer patients. According to an enquiry by Pulse magazin...

  • Vifor and Grünenthal ‘Named and Shamed’ for Breaking ABPI Code

    Jul 09, 2012 Pharmaceutical companies Grünenthal and Vifor have been 'named and shamed' in numerous publications for breaking the Association of the British Pharmaceutical Industry's (ABPI’s) Code of Practice. Grünenthal has been criticised for the way in which their team of health economic liai...

  • Research Study Reveals Medication Warning Labels Require Overhaul

    Jul 05, 2012 Numerous patients appear to overlook prescription drug warning labels with directions that are vital for safe and effective use, a research study by scientists at Michigan State University and a Kansas State University researcher have found. Patients, predominantly older ones, frequently ignore pre...

  • Ferring Obtains Rights to Albireo’s Elobixibat

    Jul 03, 2012 Ferring Pharmaceuticals announced yesterday that they have acquired the rights of Albireo’s elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). The arrangement provides Ferring with the rights to market the pr...

  • NHS Must Recognise and Enhance the Role of Generalists

    Jun 27, 2012 The important job of a ‘medical generalist’, or ‘expert in whole-person medicine’, needs to be more commonly acknowledged and improved if the NHS are to meet the challenges facing them, a new report published by the RCGP stresses. The importance and influence of medical gene...

  • Drug Shortages Experienced in 80% of NHS Trusts

    Jun 25, 2012 Eighty per cent of sixty National Health Service (NHS) trusts in England and Wales are facing “unacceptable” delays in locating drugs for patients, freedom of information requests by Labour MP Huw Irranca-Davies have exposed. About 70 to 80 drugs are still on the at risk list, including...

  • BAPW Urges Department of Health to Provide Leadership on Drug Shortages

    Jun 21, 2012 The Department of Health needs to “stop sticking its head in the sand” regarding the problem of drug shortages, the British Association of Pharmaceutical Wholesalers (BAPW) has stressed. “We work in a supply chain which presents many conflicting incentives, and we must have leader...

  • Pfizer's Xalkori Extends Lung Cancer Patient Survival

    Jun 19, 2012 Pfizer yesterday revealed information that demonstrates that Xalkori considerably improved progression-free survival in previously-treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Xalkori (crizotinib) gained approval by the US Food and Dru...

  • Clinical Research 'Health Check' Tool for Trusts Introduced by NIHR

    Jun 13, 2012 The National Institute for Health Research Clinical Research Network (NIHR CRN) are introducing a new device to show National Health Service (NHS) Trusts in England how well they are delivering across different therapy areas on their responsibility to encourage clinical research trials. The initiat...

  • NHS Public Satisfaction Rates Tumble

    Jun 11, 2012 Public satisfaction regarding how the NHS functions across the UK dropped by 12% last year, to 58% from 70% in 2010, according to the most recent British Social Attitudes Survey. This is the largest decrease in one year from when the survey started in 1983, although it still remains the third highe...

  • Study Finds European Healthcare "Better Than Ever"

    Jun 07, 2012 In spite of the financial crisis, healthcare across Europe continues to improve, with consumer empowerment motivating advances in quality and access. However, the distribution of cancer drugs within the UK is still "deplorable," states a new review, presented at the European Parliament in Brussels....

  • Patient Support Programmes Create Better Results

    May 29, 2012 Patient support programmes (PSP) which involve patients paying part of the fee for their prescription drugs, provide better outcomes than programmes that allow patients to obtain their medication entirely free, eyeforpharma’s Patient Summit conference heard. Patient support programmes offer s...

  • Teva Reduces 2012 Profit Forecasts

    May 24, 2012 Teva Pharmaceuticals yesterday announced that they have reduced their sales and earnings predictions for 2012 partly as a result of pricing problems and currency effects in Europe. The organisation is now forecasting earnings in the range of $5.30-$5.40 per share, down from prior guidance of $5.48-...

  • Essential Drugs Unavailable as Greek Pharmacists Strike

    May 22, 2012 Approximately 163 critical drugs are now unobtainable from pharmacies in Greece, sector leaders stated, in advance of the country's pharmacists' planned one-day strike today. Drugstores in Greece are closed today as owners demonstrate against the fact that social security funds are yet to pay their...

  • Auranofin 'Promising' to Treat Amoebic Dysentery

    May 20, 2012 Auranofin, a common and cheap drug currently used for arthritis, could help fight against parasitic organisms responsible for amoebic dysentery, according to US researchers. Amoebic dysentery is caused by Entamoeba histolytica, which infects the bowels.  It results in severe diarrhoea as well ...

  • Campaigners Target Andrew Lansley at NICE Conference

    May 16, 2012 Unrest over the government’s health bill came to the fore again at this week’s NICE conference, with one protestor questioning the UK Health Secretary over his rejection to issue the NHS risk register during his speech to delegates yesterday. This is the second time that the Health Secr...

  • Merck KGaA Targets 300 Million Euros Cost Savings as Profits Fall

    May 14, 2012 Merck KGaA has revealed information regarding their new restructuring strategy and is targeting cost savings of 300 million euros at their drugs unit by 2014. Karl-Ludwig Kley, Chairman of the German organisation, noted that they face “unprecedented market shifts and increasing competition in...

  • NHS Could Save £350 Million Yearly From Generic Lipitor

    May 10, 2012 The admittance of generic forms of Pfizer's cholesterol lowering drug, Lipitor (atorvastatin), onto the UK market could in time save the NHS £350 million annually. According to the Generic Manufacturers' Association, the loss of Lipitor's patent protection in the UK and the accessibility of l...

  • UK Researchers Halt Brain Cell Death in Mice

    May 08, 2012 UK researchers have exposed the basis of what could become a new method to treat degenerative brain illnesses such as Alzheimer's and Parkinson's. Scientists from the University of Leicester have, by tackling a new pathway, managed to stop brain cell death in mice with prion disease, a progressive ...

  • MHRA Reveals New Strategy to Crack Down on Fake Drugs

    May 02, 2012 The MHRA (Medicines and Healthcare products Regulatory Agency), a government agency responsible for ensuring that medicines and medical devices work and are acceptably safe, has revealed their new anti-counterfeiting policy to increase the clamp down on fake drugs arriving in the UK supply chain. D...

  • Watson Pharmaceuticals Announces Strong First Quarter

    Apr 30, 2012 Watson Pharmaceuticals, which are currently in the procedure of acquiring generics firm Actavis for 4.25 billion euros, announced strong earnings and revenue increases for their first quarter on Monday. The company’s net income was up by 22% from $45.3 million to $54.8 million, while revenues...

  • Strong Vyvanse Sales Boost Shire’s First Quarter

    Apr 26, 2012 Shire posted another strong set of results yesterday, with a 20 percent rise in first-quarter earnings, just beating market expectations, and their attention-deficit hyperactivity disorder (ADHD) treatments and rare disease drugs once again performing well. Shire, whose development has outstripped ...

  • GlaxoSmithKline Announce Q1 Results

    Apr 24, 2012 Pharmaceutical drug maker, GlaxoSmithKline (GSK), today announced that their revenue increased just 1% in the first quarter, reflecting burdens on the organisation from government price cuts in Europe and some emerging markets, and hard year-by-year comparisons. GSK’s results were boosted by ...

  • The Department of Health Moves to Secure Quicker Access to Cancer Drugs Fund

    Apr 23, 2012 The Department of Health has issued new guidance on the Cancer Drugs Fund which, it says, should help National Health Service patients in England gain much faster access to innovative medicines. Launching the new guidance earlier this week, Health Minister Lord Howe commented that applications to t...

  • GlaxoSmithKline Retains Friendly Approach, Despite Hostile HGS Bid

    Apr 19, 2012 In confirming its unsolicited $2.60 billion offer for Human Genome Sciences (HGS), which was rejected, GlaxoSmithKline (GSK) commented that they still hope to push through the bid “on a friendly basis.” The UK drugs manufacturer noted that the $13.00 per share offer represented an 81% p...

  • Johnson & Johnson Profits Increase

    Apr 17, 2012 Johnson & Johnson (J&J) yesterday reported a 12.5% growth in earnings for their first quarter, assisted by sales of new products, the most noticeable being the prostate cancer drug Zytiga. The group’s net earnings came in at $3.91 billion, while turnover fell 0.2% to $16.14 billion.&n...

  • Only Medics’ Mobile Website Is Now Live

    Apr 15, 2012 To further enhance our services we today have launched our new mobile website, offering candidates an easier alternative when searching for their next pharmaceutical physician vacancy using their mobile. With an increasing number of people accessing the internet via their mobiles, Only Medics, as t...

  • Study Shows Huntington's Reduces Cancer Risk

    Apr 11, 2012 According to a study in Sweden, people who have developed Huntington's disease, a debilitating brain condition, appear have a "protection" from cancer. The findings, which were published in The Lancet Oncology, analysed almost 40 years of medical records, showing that patients with Huntington&rsquo...

  • Lansley Urges NHS Groups To Use New Power And Freedom To Innovate

    Apr 09, 2012 Over half of future NHS commissioning funds have already been delegated to clinical commissioning groups (CCGs), "and the number is rising all the time," Health Secretary Andrew Lansley has told CCG clinical and managerial leads. Mr Lansley wrote to Clinical Commissioning Groups highlighting the fr...

  • Eisai Joins Up With Valeant To Promote Halaven

    Apr 03, 2012 After failing to gain approval from UK cost watchdog, NICE, for the use of Halaven in treating breast cancer, Eisai has linked up with Valeant Pharmaceuticals International, to promote the drug in Central and Eastern Europe. Halaven received European Commission approval in March 2011. Valeant's Ph...

  • Court of Justice Finds Poland's Low-cost Treatment Law Breaks EU Rules

    Apr 01, 2012 The EU Court of Justice ruled on Thursday last week that a Polish law which allows the sale of prescription medicine that has not been permitted by the European Medicines Agency (EMA) but is similar and cheaper to drugs which have, breaches European Union (EU) law. Under European law, no prescripti...

  • Boehringer Ingelheim Reduces Cost of Pradaxa by 13%

    Mar 28, 2012 Boehringer Ingelheim has announced that they will be decreasing the price of their oral anticoagulant Pradaxa (dabigatran etexilate) by 13% to £2.20 per day, from 1st April 2012. The change comes two weeks after the National Institute for Health and Clinical Excellence (NICE) issued a final g...

  • UK Government Increases Funding For Dementia Research

    Mar 26, 2012 The UK government has pledged to more than double annual funding for research into dementia and neurodegenerative diseases to over £66 million by 2014/15, in an increase from £26.6 million in 2009/10. The commitment was announced yesterday by the UK Prime Minister, David Cameron, as par...

  • Lung Cancer Detection Trial Announced For Smokers

    Mar 23, 2012 A simple blood test which can identify lung cancer five years before conventional screenings will be trialled by the NHS on 10,000 high risk smokers. The trial is being tested in Scotland in the anticipation that it could provide the first national screening programme for lung cancer in addition to...

  • UK MPs Approve Controversial NHS Bill

    Mar 21, 2012 The NHS health bill has survived the final parliamentary test and is set to become law. Labour’s call for MPs to delay their final consideration of the NHS overhaul in England until an evaluation of the potential risks is available was defeated by 82 votes. An emergency debate over the propo...

  • Medicine Access Changes Will Help Companies Develop, UK MPs Told

    Mar 15, 2012 UK MPs have been told that regulatory proposals currently being considered for quicker entrance for medicines which meet key unmet medical needs provide an opportunity for small life science businesses to grow to middle-sized organisations. In December 2011, the UK’s Prime Minister, David Cam...

  • Pharmaceutical Industry is 'Safe Haven' for Investors

    Mar 13, 2012 Analysts at Peel Hunt have analysed the global healthcare sector, and stated that it is in a fairly healthy condition, in spite of the pressures the industry is currently under. Contained within the report, the broker claims that the healthcare sector "has again proved its resilience in periods of ...

  • Pharmaceutical Industry Should Invest Further in Anti-Obesity Drugs

    Mar 09, 2012 Pharmaceutical organisations should increase their investment in anti-obesity drugs to respond to the rising number of clinically obese people globally. This is the main message from a report by business intelligence specialist, GlobalData, which observes that the obesity market is lucrative, large...

  • ICON’s MIRA Chosen by Roche for Medical Image Repository

    Mar 07, 2012 Continuing its move from transactional relationships to strategic alliances with clients, ICON have announced that they have been chosen by Roche as Roche’s technology partner for storing and managing medical images collected during clinical research programmes. ICON is an international suppl...

  • Only Medics To Attend DGPharMed 2012

    Mar 05, 2012 Only Medics will be attending DGPharMed’s annual conference at the Hotel Pullman Cologne, in Germany on the 8th and 9th March 2012.2012 sees the 28th year of the annual conference by the German Society of Pharmaceutical Medicine.The conference starts at 9:20am on Thursday 8th March, and finish...

  • UK’s NICE Dismisses Drug Delay Statements

    Mar 01, 2012 The UK’s National Institute for Health and Clinical Excellence (NICE) has not been requested to alter the basis of their assessments "simply to save money," NICE’s chief executive, Sir Andrew Dillon, has stated. Sir Andrew Dillon was replying to media reports from earlier this week, whi...

  • Only Medics at the 2012 BrAPP Annual Symposium

    Feb 28, 2012 Only Medics will be attending this year’s BrAPP Conference on 1st March 2012 in London.2012 sees BrAPP celebrating its 55th year as the professional association for pharmaceutical physicians.The conference starts at 9am, and is followed by a three course dinner with guest speaker, Professor Tr...

  • Study Finds Selected Dementia Antipsychotics Raise Death Risks

    Feb 24, 2012 Nursing home residents over 65 who take certain antipsychotics for dementia are at an increased risk of death, according to a recent study by the Harvard Medical School involving 75,445 patients. In a paper published on bmj.com, the study, which was the largest ever undertaken among US nursing home...

  • Berkeley Lab Discover New Evidence On How ‘Good’ Cholesterol Turns ‘Bad’

    Feb 22, 2012 Researchers with the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have discovered new proof to clarify how cholesteryl ester transfer protein (CETP) mediates the move of cholesterol from "good" high density lipoproteins (HDLs) to "bad" low density lipoproteins (LD...

  • Health Inequalities Increase, As Experts Warn Over Health Plans

    Feb 16, 2012 Two years after the Marmot Review Fair Society, Healthy Lives was released, new data revealed yesterday illustrates that health inequality between the poor and the rich are continuing to grow, although there has been an improvement in average life expectancy.According to figures from the Institute o...

  • US green light for Merck & Co's eye drug Zioptan

    Feb 14, 2012   The US Food and Drug Administration has given the nod to Merck & Co's eye solution Zioptan for lowering intraocular pressure in patients with certain eye conditions. Shares in the drugmaker were given a bump after it announced that Zioptan (tafluprost ophthalmic solution) 0.0015%...

  • Eisai Receives Positive Alzheimer Study Results, While FDA Rejects Dacogen

    Feb 10, 2012 Eisai has received mixed news this week, after news that Dacogen, Eisai and Astex Pharmaceuticals’ drug to treat a type of leukaemia, has been rejected by an independent advisory panel to the regulator in the USA.The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Commit...

  • Osteoporosis Market Predicted To Grow To $11.4B By 2015

    Feb 08, 2012 The global market for osteoporosis drugs is expected to increase from $7.3 billion in 2010 to $11.4 billion by 2015, according to new estimates. The market will achieve an average annual growth of 9.2% during this period, according to the report published by Transparency Market Research. The stud...

  • Competition Could Benefit the NHS, Declares the Office of Health Economics

    Feb 02, 2012   Competition can help the integration of care in the NHS, and there is no proof that it would hinder it, according to a new report from the Office of Health Economics. The report analyses the conclusions of the Commission on Competition in the NHS, which was assembled by the OHE (Office of...

  • New Children's Health Outcomes Strategy Planned By UK Government

    Jan 31, 2012 The UK government has revealed new plans for a focus to improve health care for children and young people.The ‘Children's and Young People's Outcomes Strategy’, which will be unveiled later in the year, will concentrate on improving healthcare service outcomes for children, including tho...

  • Our Latest Advert in BrAPP January 2012

    Jan 26, 2012 Our newest advert has been published in the latest issue of BrAPP's Pharmaceutical Physician Magazine. It can be downloaded in our Brochure and latest adverts section. Tell us what you think!...

  • Frost & Sullivan Study Finds Major Development Potential for European CMOs

    Jan 25, 2012 The European pharmaceutical contract manufacturing market made revenues of $10.02 billion in 2011, and this figure is expected to double to $20.75 billion by 2018, according to new forecasts.Over the same time period, the European market for biotechnology contract manufacturing is expected to increa...

  • BAPW Appeal for Objective Monitoring of Branded Medicine Supplies

    Jan 19, 2012 The BAPW (British Association of Pharmaceutical Wholesalers) has appealed for pharmacies and manufacturers to support third-party monitoring and reporting of branded drug supplies.Critical deliberation should be given to the establishment of a robust, objective monitoring and survey service of medic...

  • Hospital Patient Service Cuts Are Hard To Defend, Says Nuffield Trust Report

    Jan 17, 2012 Cuts in patient services are difficult to rationalise when there are many ways hospitals could improve their efficiency, a major new evaluation prepared for the Nuffield Trust by Jeremy Hurst and Sally Williams has concluded.While inefficiencies in areas such as rates of day case surgery, length of ...

  • Investigative Sites Continued to Shrink Over Last Five Years

    Jan 11, 2012 The international landscape for investigative sites, research centres that conduct clinical research, has continued to decline over the past five years, according to US-based information services provider CenterWatch.The global economic downturn is combining with decreasing study numbers, budget pre...

  • European GPs Are Concerned That Health Systems Will Fail As Population Ages

    Jan 05, 2012 Roughly 80% of doctors are concerned about how they will be treated when they grow old and fear that present guidelines to deal with the ageing population are not "comprehensive, realistic or sufficiently funded to address future demand".That is one of the main findings of a recent study from the Ec...

  • "Choose your GP" Pilots Announced for April

    Jan 03, 2012 UK Health Secretary, Andrew Lansley, has announced that one-year pilot schemes for a new initiative which allow patients to choose their GP practice will start in April this year. The trials, which will run in parts of central London, Manchester/Salford and Nottingham, will allow the public, for ...

  • European Proposals Would "Give More Scope for Negotiation" says the NHS

    Dec 22, 2011 The EU’s (European Union) proposal for a new directive on public procurement will permit "more scope for negotiating with suppliers," according to the NHS Confederation. The plans, which have been published by the European Commission this week, contain a number of provisions intended to sim...

  • Multiple Myeloma Therapy Market Set For "Robust" Annual Growth

    Dec 21, 2011 The multiple myeloma drug therapy market will experience robust growth averaging 5.6% annually from 2010 to 2020 in seven of the world’s major markets, according to new projections. Growth in these markets - US, Italy, Spain, UK, France, Germany and Japan - will be driven by additional pene...

  • Merry Christmas, from the Only Medics Team

    Dec 20, 2011 We would like to wish all of Only Medics' clients and candidates a very Merry Christmas and Best Wishes for the New Year. Thank you for your business in 2011 and we look forward to working with you in 2012!Please note the following office hours:Only Medics will be closed from midday on Friday, 23r...

  • NHS To Receive £2.5 Billion Funding Boost for 2012-2013

    Dec 20, 2011 The NHS is to gain a funding boost of over £2.5 billion to deliver services to patients in 2012-13, Health Secretary Andrew Lansley has announced. £91.6 billion will be given to Primary Care Trusts, representing a 2.8% rise in total allocations.  The funding breaks down as follow...

  • Galapagos Reaches Milestone in Servier Osteoarthritis Agreement

    Dec 16, 2011 Galapagos of Belgium yesterday announced that they have reached milestones in its osteoarthritis alliance with Servier, resulting in a payment of 4 million euros from the French drugmaker.In July 2010, teamed up for a collaboration that could be worth around 300 million euros to the Mechelen-based g...

  • Challenging 2012 Predicted for the Pharmaceutical Industry

    Dec 15, 2011 Ratings agency Fitch has issued a report predicting that the pharmaceutical sector will "continue to experience significant operating challenges" in 2012 but while issuing a negative outlook, they added that pharmaceuticals will still be one of the highest-rated industries. The new analysis comme...

  • UK Audit Finds That Lung Cancer Care is Improving Every Year

    Dec 13, 2011 The National Lung Cancer Audit announced that the proportion of patients receiving key care measures, such as surgery or anti-cancer treatment like chemotherapy or radiotherapy, is improving each year.58.4% of patients with lung cancer in England and Wales and 63.9% in Scotland received an anti-canc...

  • Haemophilia B Gene Therapy Injection Shows Initial Success

    Dec 12, 2011 A small trial which shows that symptoms improved considerably in adults with the bleeding disorder haemophilia B, after a single treatment with gene therapy, has caused excitement among the scientific community.A single treatment with gene therapy developed by researchers at St Jude Children's Resea...

  • Only Medics' Sister Company, Clinical Professionals, Achieves Sunday Times Fast Track 100 Top 50 Ranking

    Dec 12, 2011 Fast Track, in association with the Sunday Times, has this week revealed Britain’s fastest growing private firms. Only Medics' sister company, Clinical Professionals, was ranked in the Top 50 within The Sunday Times Virgin Fast Track 100 league table for 2011.The league table ranks Britain&rsq...

  • Johnson & Johnson To Pay Nearly $1 Billion for Pharmacyclics' Cancer Drug

    Dec 09, 2011 Johnson & Johnson have entered into an agreement to help develop a cancer compound discovered by Pharmacyclics in a deal that could be worth close to $1 billion to Pharmacyclics.Johnson & Johnson's Janssen Biotech subsidiary will work together to develop and market the drug, known as PCI-327...

  • Roche Set Up Swiss Academic Translational Centre

    Dec 08, 2011 Roche yesterday announced that they are increasing their collaborative efforts with academic researchers to deliver the next generation of targeted therapies for unmet medical needs by creating an external academic translational research hub in their home market. The hub in Zurich, Switze...

  • Lifestyle Choices Cause More Than 100,000 Cancers Each Year

    Dec 07, 2011 A report by Cancer Research has revealed that 40% (100,000) of cancers diagnosed annually in the UK are caused by a person's lifestyle choice and could potentially have been prevented.  The main causes of the cancers included smoking, eating the wrong type of daily diet, and drinking alcohol.Th...

  • Pharmaceutical Industry Receives Boost from UK Government Plans to Improve Medicine Access

    Dec 06, 2011 Earlier access to new medicines and automatic inclusion of NICE-recommended treatments onto local formularies are some of the many measures included in a package announced yesterday by the UK Prime Minister, David Cameron, as part of the UK's Life Sciences Strategy and the NHS Chief Executive, Sir D...

  • Eli Lilly Conduct Study into the Barriers of Progression in Insulin Treatment

    Dec 02, 2011 Eli Lilly and Company yesterday announced that they are conducting the first major international, prospective observational study intended to understand the real-world difficulties that people with type 2 diabetes face that result in preventing them from attainment their ultimate treatment goals. ...

  • NHS Urge Improved Joint Working with Pharma

    Dec 01, 2011 Joint working with pharmaceutical companies should be "explicitly" positioned as an enabler of clinical commissioning, according to the NHS. The ethos and local emphasis of the NHS / industry joint working initiatives are closely aligned with the values of clinical commissioning, and their foc...

  • Pharmaceutical Google+ Pages

    Nov 21, 2011 As Google+ becomes a more integrated part of our on-line searches, we thought we would list here the major Pharmaceutical companies with a dedicated page up on the network. Adding them to your circles will allow you to follow their latest research updates as well as any developments the pharmace...

  • Only Medics now on Google+

    Nov 09, 2011 Only Medics have recently created a dedicated page on Google+ Add us to your circles to be kept up to date on the latest careers and industry news for pharmaceutical physicians. Only Medics are the forefront of their field, of which we hope this we become another useful networking and informatio...

  • New Only Medics Article - The Interim

    Nov 07, 2011 Following on from our successful line of articles, a pharmaceutical physician from the industry has written an article for us on the subject of Interims. A very insightful read for those looking to move their career in this direction or wishing to know more information on the topic. Just head to...

  • Latest BrAPP Advert now Published (September 2011)

    Sep 11, 2011 Following on from our new set of advert designs, our new BrAPP advert is now live. Read the latest issue of Pharmaceutical Physician to see it in print, or download it from the 'Brochure and Latest adverts' Section of the website....

  • Social Media Focus

    Jul 25, 2011 Only Medics continues to see an increase in group numbers for our social media groups. We now have a number of groups on LinkedIn and a Twitter group to assist candidates looking for employment. After becoming one of the first pharmaceutical recruitment companies to network using LinkedIn grou...

  • Only Medics in the National Online Recruitment Awards 2011

    Jun 23, 2011 Only Medics have recently been entered in for the National Online Recruitment Awards, NORA. Established in 2001, NORA reward the excellence in the UK online recruitment process, that has been unparalleled anywhere else in the world. We are delighted to be a part of these prestigious awards,...

  • New Website now Live.

    Jun 01, 2011 After Months of Planning and feedback from Only Medics and our clients and contacts we are proud to present our new website. We feel it is a vast improvement on the old structure, and allows for much easier navigation and focus on the areas important to yourselves. We hope we continue to be a us...

  • Latest BrAPP Advert now Published (May 2011)

    May 18, 2011 Our latest BrAPP advert is was very warmly received in the latest issue of Pharmaceutical Physician. It is now also available as a PDF download in our Brochure and Adverts section....

  • Latest BrAPP Advert now Published (March 2011)

    Feb 09, 2011 Our latest advert to be published in the BrAPP pharmaceutical Physician Magazine is now available in the Brochure and Adverts section of the website....

Job Search

Advanced job search

Register your C.V.